Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and GD of Intraperitoneal Portal Insulin U-500 in Type 1 Diabetes
NCT07341373Phase 1Completed
- Sponsor
- Portal Diabetes
- Start
- Feb 2026
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin regular human U-500 in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Portal Diabetes. Primary endpoints: Incidence of adverse events at 2 months, Change from baseline in systolic and diastolic blood pressure and 15 more. Started Feb 2026; status: completed.
02
Drugs
insulin regular human U-500
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07341373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341373.